insights_auto
Why is 22UA down 2.42%?
Dive Deeperchevron_right
22UA:ETR
BioNTech SE - ADR
€78.60
arrow_downward
-2.42%(-1.95) 1D
Oct 16, 5:35:51 PM GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 22UA...
Open
€80.75
High
€81.15
Low
€78.40
Mkt. cap
22.03B
Avg. vol.
26.41K
Volume
12.88K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
Open
€80.75
High
€81.15
Low
€78.40
Mkt. cap
22.03B
Avg. vol.
26.41K
Volume
12.88K
52-wk high
€105.70
52-wk low
€68.30
No. of employees
8K
News stories
From web sources and news partners
ad-hoc-news.de
·
9 hours ago
BioNTech schedules November 3 results. BioNTech stock sits 29.27 percent below its high
Yahoo Finance
·
10 hours ago
Move Aside, Moderna: This mRNA Stock Is Sitting on a Cash Pile and a Deep Cancer Pipeline
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR